LifeMD, Inc. (LFMD)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$3.08+0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Broken: Primary pillar broken — Revenue growth to $220M-$230M in fiscal 2026: FY26 rev guide $205.5M-$212.5M vs $220M target.
LifeMD aims to grow revenue to $220M-$230M in 2026. Revenue rose from $20.3M in 2025-Q4 to $50.2M in 2026-Q1. The company secured a $30M credit facility to support growth. A new CTO appointment supports technology and growth initiatives.
LifeMD is still loss-making with negative free cash flow. The company missed earnings in recent quarters. Growth depends on successful execution of new partnerships and credit use. Risks include litigation and management transitions.
The market expects about 22% revenue growth next year. Our fair value of $23.11 aligns with consensus revenue growth but reflects elevated risk from losses and execution challenges.
Breaks if: Credit facility remains unused or misused, failing to support growth
Breaks if: CTO departure or failure to advance technology growth initiatives
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation. LFMD is currently experiencing weak financial performance and high risk, but it has opportunities for growth through strategic partnerships and product launches.
The market seems to have priced in a low level of execution quality, reflecting a cheap valuation compared to peers. There is an expectations gap indicating that the market anticipates weaker performance than what might be achievable.
Management aims for revenue growth and improved adjusted EBITDA, but recent results have shown downward revisions in guidance. The near-term risk is moderate, with a low probability of missing expectations, although the company operates in a smaller-cap space with higher volatility.
The future performance of LFMD depends on whether it can reverse its recent guidance cuts and improve execution. Additionally, broader sector momentum and the performance of key competitors will play a significant role in shaping LFMD's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on LFMD. However, analysts lowered targets due to weaker guidance, which threatens the outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Annual revenue falls below $220 million in FY26
Over the next 1 to 3 years, LFMD's outlook is mixed, hinging on management's ability to execute on their growth strategies and external market conditions. Not investment advice.